[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-346779-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-346779-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","crosstalk-between-kras-and-mirnas-in-pancreatic-cancer-opportunities-for-its-diagnosis-prognosis-and-therapeutic-intervention-review","Crosstalk between KRAS and miRNAs in pancreatic cancer - Opportunities for its diagnosis, prognosis and therapeutic intervention - Review","","Pancreatic cancer, mainly pancreatic ductal adenocarcinoma (PDAC), is an aggressive malignancy in which dysregulated crosstalk between KRAS and microRNAs (miRNAs) drives key disease behaviors. Activating KRAS mutations are present in ~90% of cases and function as molecular switches that promote proliferation, survival, migration and transformation. In parallel, aberrant KRAS-targeting miRNA regulation amplifies RAS signaling and supports tumor initiation, progression and metastasis. Tumor-suppressive miRNAs can suppress PDAC in vitro and in preclinical models. Yet miRNA-based therapies and circulating miRNA biomarkers remain insufficiently established in patients, creating opportunities for diagnosis, prognosis and therapeutic intervention through focused targeting of KRAS-miRNA networks.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/crosstalk-between-kras-and-mirnas-in-pancreatic-cancer-opportunities-for-its-diagnosis-prognosis-and-therapeutic-intervention-review/346779/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/crosstalk-between-kras-and-mirnas-in-pancreatic-cancer-opportunities-for-its-diagnosis-prognosis-and-therapeutic-intervention-review/346779.png","ImageObject",300,407,{"name":42,"@type":43},"Ivy","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is KRAS-miRNA crosstalk important in pancreatic cancer?","Question",{"text":63,"@type":64},"Dysregulated KRAS signaling is amplified by KRAS-targeting miRNAs, which promotes tumor initiation, progression, metastasis, and treatment resistance in PDAC.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How common are KRAS mutations in PDAC?",{"text":68,"@type":64},"Activating KRAS mutations occur in about ~90% of PDAC cases and act as molecular switches that activate multiple intracellular signaling cascades.",{"name":70,"@type":61,"acceptedAnswer":71},"What opportunities does the review highlight for diagnosis and prognosis?",{"text":72,"@type":64},"Circulating miRNAs are presented as promising non-invasive biomarkers for detecting disease, monitoring progression, and assessing tumor aggressiveness, supporting improved diagnosis and prognosis strategies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},346779,1790417792,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","INTERNATIONAL JOURNAL OF ONCOLOGY 68: 60, 2026  \nCrosstalk between KRAS and miRNAs in pancreatic cancer: Opportunities for its diagnosis, prognosis and therapeutic intervention (Review)  \nABDULAZIZ A. ALOLIQI 1 , ABDULLAH M. ALNUQAYDAN 1 , MOHAMMAD ALSHEBREMI2 , ARSHAD HUSAIN RAHMANI2 and AMJAD ALI KHAN 1  \n1  \nDepartment of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia; 2  \nDepartment of Medical Laboratories, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia  \nReceived December 11, 2025; Accepted March 3, 2026  \nDOI: 10.3892/ijo.2026.5873  \nAbstract. Pancreatic cancer, predominantly manifested as pancreatic ductal adenocarcinoma (PDAC), is a highly aggres‑ sive malignancy in which the dysregulated crosstalk between Kirsten rat sarcoma viral oncogene homolog (KRAS) and microRNAs (miRNAs) plays a critical role. It is one of the leading causes of cancer‑related mortality worldwide, with its global incidence more than doubling over the past 25 years. PDAC is characterized by rapid progression, invasiveness and profound resistance to conventional therapies, resulting in dismal prognosis. Its genetic profile is characterized by activating KRAS mutations, present in ~90% of cases. These mutations act as molecular switches that activate multiple intracellular signaling cascades and transcription factors, promoting uncontrolled proliferation, survival, migration and transformation. In addition to direct KRAS alterations, dysreg‑ ulation of KRAS‑targeting miRNAs further amplify aberrant RAS signaling. Emerging evidences highlights the significant role of miRNAs in driving tumor initiation, progression and metastasis. Several tumor‑suppressive miRNAs that regulate KRAS signaling have demonstrated the capacity to suppress pancreatic tumor development in vitro and in preclinical models. Despite these advances, miRNA‑based therapies, including mimics or anti‑miRNA oligonucleotides targeting KRAS, remain largely unexplored in patients with PDAC. Further, circulating miRNAs show promise as non‑invasive biomarkers for disease detection, monitoring progression and assessment of tumor aggressiveness. The present review provided a concise overview of KRAS signaling and its  \nCorrespondence to: Dr Amjad Ali Khan, Department of Basic Health Sciences, College of Applied Medical Sciences, Qassim University, Buraydah 51452, Saudi Arabia  \nE‑mail: [akhan@qu.edu.sa](akhan@qu.edu.sa)  \nKey words: cancer, pancreatic cancer, pancreatic ductaladenocarcinoma, Kirsten rat sarcoma viral oncogene homolog, microRNA, signaling pathway  \nfrequent mutations in PDAC, examines strategies to target KRAS and discussed the crosstalk between KRAS and tumor‑suppressive miRNAs in regulating pancreatic tumori‑ genesis. It further explored diagnostic and prognostic miRNAsin pancreatic cancer. Collectively, these insights underscored the potential of miRNA‑based interventions to improve early detection, prognosis and targeted therapy in this lethal disease.  \nContents  \n1. Introduction  \n2. KRAS‑driven signaling in pancreatic ductal cells  \n3. KRAS driven signaling and the role of miRNAs  \n4. Feedback loops and reciprocal regulation between KRASand miRNAs  \n5. Role of KRAS in pancreatic cancer  \n6. Targeting KRAS for treatment  \n7. Paradigm shift towards understanding the role of miRNA in PDAC  \n8. Overview of miRNA structure, biogenesis and mechanism of action  \n9. Role of miRNAs in pancreatic cancer  \n10. Regulation of signaling via miRNAs  \n11. miRNAs targeting KRAS  \n12. miRNAs for pancreatic cancer therapy  \n13. miRNAs as PDAC biomarkers  \n14. miRNAs as PDAC prognostic factors  \n15. Clinical trials involving KRAS and miRNAs in pancreatic cancer  \n16. Future perspectives  \n17. Conclusion  \n1. Introduction  \nPancreatic ductal adenocarcinoma (PDAC) is highly lethal, contributing to >400,000 mortalities across the globe each year. Epidemiological projections from North America a","cbCaiho963ye84TS","https://ap.wps.com/l/cbCaiho963ye84TS","pdf",2349326,25,"English","# Contents\n## Introduction\n## KRAS-driven signaling in pancreatic ductal cells\n## KRAS driven signaling and the role of miRNAs\n## Feedback loops and reciprocal regulation between KRAS and miRNAs\n## Role of KRAS in pancreatic cancer\n## Targeting KRAS for treatment\n## Paradigm shift towards understanding the role of miRNA in PDAC\n## Overview of miRNA structure, biogenesis and mechanism of action\n## Role of miRNAs in pancreatic cancer\n## Regulation of signaling via miRNAs\n## miRNAs targeting KRAS\n## miRNAs for pancreatic cancer therapy\n## miRNAs as PDAC biomarkers\n## miRNAs as PDAC prognostic factors\n## Clinical trials involving KRAS and miRNAs in pancreatic cancer\n## Future perspectives\n## Conclusion","[{\"question\":\"Why is KRAS-miRNA crosstalk important in pancreatic cancer?\",\"answer\":\"Dysregulated KRAS signaling is amplified by KRAS-targeting miRNAs, which promotes tumor initiation, progression, metastasis, and treatment resistance in PDAC.\"},{\"question\":\"How common are KRAS mutations in PDAC?\",\"answer\":\"Activating KRAS mutations occur in about ~90% of PDAC cases and act as molecular switches that activate multiple intracellular signaling cascades.\"},{\"question\":\"What opportunities does the review highlight for diagnosis and prognosis?\",\"answer\":\"Circulating miRNAs are presented as promising non-invasive biomarkers for detecting disease, monitoring progression, and assessing tumor aggressiveness, supporting improved diagnosis and prognosis strategies.\"}]","Crosstalk between KRAS and miRNAs in pancreatic cancer - Opportunities for its diagnosis, prognosis and therapeutic intervention - Review | PDF",1790062713,63,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9e2fa92016ed5d71c4981a7e9e1a8259.webp",983,1357,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d8492bceab8f9a1385755c207ea8744.webp",982,1356,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d23ac35c1ee42dd50daa2d0f243dc2ec.webp",981,1354,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1110348b6d2811548c8d11b3340413cc.webp",980,1353]